Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors

被引：0
|
作者：
Wang, J. [1 ]
Johnson, M. [2 ]
Barve, M. [3 ]
Pelster, M. [2 ]
Chen, X. [4 ]
Li, Z. [4 ]
Gordon, J. [4 ]
Reiss, M. [4 ]
Pai, S. [4 ]
Falchook, G. [5 ]
Tolcher, A. [6 ]
机构：
[1] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Tennessee Oncol Drug Dev Unit, Nashville, TN USA
[3] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[4] Erasca Inc, San Diego, CA USA
[5] Sarah Cannon Res Inst HealthONE, Drug Dev Unit, Denver, CO USA
[6] NEXT Oncol, Oncol, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [31] Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study
    Oberstein, Paul Eliezer
    Moreno, Victor
    Raghav, Kanwal Pratap Singh
    Hong, Yong Sang
    Han, Sae-Won
    Su, Yu-Li
    Yuan, Ying
    Pietrantonio, Filippo
    Van Cutsem, Eric
    Eng, Cathy
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Bhattacharya, Rianka
    Maul, Raymond Scott
    Iwasawa, Ryota
    Schnepp, Robert W.
    Knoblauch, Roland Elmar
    Thayu, Meena
    Ho, Gwo Fuang
    Kim, Han Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 135 - 135
  • [32] A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Mingxiang Liao
    Krzysztof G. Jeziorski
    Monika Tomaszewska-Kiecana
    István Láng
    Marek Jasiówka
    Viera Skarbová
    Piotr Centkowski
    Rodryg Ramlau
    Maria Górnaś
    John Lee
    Sarah Edwards
    Jenn Habeck
    Eileen Nash
    Nikolay Grechko
    Jim J. Xiao
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 887 - 897
  • [33] Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer
    Dasari, Arvind
    Hubbard, Joleen M.
    Eng, Cathy
    Yeckes-Rodin, Heather
    Ukrainskyj, Stacey M.
    Yang, Zhao
    Schelman, William R.
    Kania, Marek K.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours
    Hong, David S.
    Kurzrock, Razelle
    Mulay, Marilyn
    Rasmussen, Erik
    Wu, Benjamin M.
    Bass, Michael B.
    Zhong, Zhandong D.
    Friberg, Greg
    Rosen, Lee S.
    ONCOTARGET, 2014, 5 (22) : 11154 - 11167
  • [35] A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Weekes, Colin D.
    Lockhard, Albert
    LoRusso, Patricia
    Murray, Elaine
    Park, Erica
    Tagen, Michael
    Mueller, Lars
    Dokainish, Hatem
    Shapiro, Geoffrey
    Burris, Howard
    CANCER RESEARCH, 2017, 77
  • [36] A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Weekes, Colin
    Lockhart, Albert
    LoRusso, Patricia
    Murray, Elaine
    Park, Erica
    Tagen, Mike
    Singh, Jatinder
    Sarkar, Indrani
    Mueller, Lars
    Dokainish, Hatem
    Shapiro, Geoffrey
    Burris, Howard
    ONCOLOGIST, 2020, 25 (10): : 833 - +
  • [37] A PHASE 1B/2, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF AN ANTI-CTLA-4 NEOBODYTM ADG116 IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/ METASTATIC SOLID TUMORS: A PRELIMINARY UPDATE
    Tolcher, Anthony
    Powderly, John
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Shang, Jin
    Wang, Xinwei
    Li, Wenda
    Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A804 - A804
  • [38] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [40] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
12345